Safety, Tolerability, Pharmacokinetics and Glucodynamics of Multiple LY900014 Formulations

Trial Profile

Safety, Tolerability, Pharmacokinetics and Glucodynamics of Multiple LY900014 Formulations

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Insulin lispro (Primary)
  • Indications Diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 13 Jun 2017 Primary endpoint ((Part A) Pharmacokinetics : Area under the Concentration Curve (AUC) of LY900014) has not been met as per the results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 13 Jun 2017 Results (n=23) presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 08 Sep 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top